血浆体外免疫吸附去除血浆中HBV：乙型肝炎患者的潜在治疗

StephenW

Biomed Res Int. 2018 Dec 23;2018:1269063. doi: 10.1155/2018/1269063. eCollection 2018.
The Removal of HBV in Plasma by Extracorporeal Immunoadsorption from Plasma: A Potential Therapy of Hepatitis B Patients.
Han Z1, Lu X1, Tang Y1, Yang Y1, Liu Q1, Cheng P2, Zhou L3, Wang Y1.
Author information

1
    State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China.
2
    Department of Laboratory, Wuhan University Hospital, Wuhan 430072, China.
3
    Animal Biosafety Level III Laboratory at the Center for Animal Experiment, Wuhan University School of Medicine, Wuhan 430071, China.

Abstract
Objective:

To establish a novel HBV specific immunoadsorbent for the removing of HBV particles.
Methods:

The anti-HBsAg monoclonal antibody was immobilized on sepharose beads to produce a sepharose anti-HBs column. Then the immunoadsorbent was evaluated and characterized by scanning electron microscopy. In addition, time-dependent effects of the eradication capacity of anti-HBsAg functionalized sepharose beads against HBV were investigated.
Results:

Proposed immunoadsorbents exhibited a favorable biocompatibility as well as specificity. With the optimized recycle time, the decontamination performance of HBV particles and quantity of HBsAg were assessed either by real-time quantitative PCR or ELISA, which showed that the immunoadsorbent could remove approximately 90% of the HBV and 90% of the HBsAg from human plasma samples.
Conclusions:

All these results indicated that the novel immunoadsorbent could effectively remove HBV particles and likely serve as a novel therapy option or at least supplementary for the treatment regimen of HBV.

PMID:
    30671444
PMCID:
    PMC6323487
DOI:
    10.1155/2018/1269063

StephenW

Biomed Res Int。 2018年12月23日; 2018年：1269063。 doi：10.1155 / 2018/1269063。 eCollection 2018。
血浆体外免疫吸附去除血浆中HBV：乙型肝炎患者的潜在治疗方法。
韩Z1，陆X1，唐Y1，杨Y1，刘Q1，程P2，周L3，王Y1。
作者信息

1
    武汉大学生命科学学院现代病毒学研究中心病毒学国家重点实验室，武汉430072
2
    武汉大学医学院实验室，武汉430072
3
    武汉大学医学院动物实验中心动物生物安全三级实验室，武汉430071

抽象
目的：

建立一种新型HBV特异性免疫吸附剂，用于去除HBV颗粒。
方法：

将抗HBsAg单克隆抗体固定在琼脂糖珠上以产生琼脂糖抗-HBs柱。然后通过扫描电子显微镜评估和表征免疫吸附剂。此外，研究了抗HBs​​Ag功能化琼脂糖珠对HBV的根除能力的时间依赖性影响。
结果：

提出的免疫吸附剂表现出有利的生物相容性和特异性。通过优化的循环时间，通过实时定量PCR或ELISA评估HBV颗粒的去污性能和HBsAg的量，这表明免疫吸附剂可从人血浆中去除约90％的HBV和90％的HBsAg。样本。
结论：

所有这些结果表明，新型免疫吸附剂可以有效地去除HBV颗粒，并且可能作为新的治疗选择或至少补充HBV的治疗方案。

结论：
    30671444
PMCID：
    PMC6323487
DOI：
    10.1155 /一百二十六万九千〇六十三分之二千〇一十八

StephenW

https://www.hindawi.com/journals/bmri/2018/1269063/

灵魂不屈

感谢分享！是不是可以这样理解，这种类似于血液透析的疗法，只要做一两次就可以达到核苷类药物半年甚至一年的疗效？虽然并不能清除肝细胞内的cccdna复制模板。